CompletedNCT00448890
Evaluation of Single and Repeat Doses of GSK729327 in Healthy Volunteers
Medication studyAges 18–55Germany + United KingdomSchizophrenia
Understand this study
Who was this study for?
This study was for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
- Listed locations
- Berlin and 1 more locationSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateNovember 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 79
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United Kingdom, Germany
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT00448890
- Official title
Show the full official title
Single-Blind, Randomised, Placebo-Controlled Two-Part Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Escalating Doses and Repeat Doses of GSK729327 in Healthy Volunteers
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Berlin, Germany · London, United Kingdom
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is GlaxoSmithKline.
Did this study involve medication?
Yes. The study involved medication, including GSK729327 and Placebo.
Who was this study for?
This study was for healthy volunteers. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.
